OMTN, Volume 28

Supplemental information

Intermittent lipid nanoparticle mRNA

administration prevents cortical dysmyelination

associated with arginase deficiency

Suhail Khoja, Xiao-Bo Liu, Brian Truong, Matthew Nitzahn, Jenna Lambert, Adam Eliav, Eram Nasser, Emma Randolph, Kristine E. Burke, Rebecca White, Xuling Zhu, Paolo G.V. Martini, Itzhak Nissim, Stephen D. Cederbaum, and Gerald S. Lipshutz



Supplementary Figure 1: Abnormalities of Hepatic Amino Acids are Improved with *ARG1* mRNA delivered by Lipid Nanoparticle B. Derangements of the urea cycle related hepatic amino acids of A) alanine, B) arginine, C) aspartate, D) citrulline, E) glutamate, and F) glutamine are improved with the LNP B *ARG1* for mRNA delivery; ornithine (G) remains reduced. (n=6-7 per group) (ARG1, arginase 1; LNP, lipid nanoparticle) Data are represented as mean ± SD.



Supplementary Figure 2: Myelin Detection with Luxol Fast Blue Demonstrates Generalized CNS Reduction in Arginase Deficiency that is Restored with mRNA Therapy. Representative images of the copper phthalocyanine dye Luxol Fast Blue staining to detect myelin in P14 mice: A) Arg1^{+/+}, B) untreated Arg1^{-/-}, C) LNP A *ARG1* mRNA treated Arg1^{-/-}, and D) LNP B *ARG1* mRNA treated Arg1^{-/-}. (CNS, central nervous system; mRNA, messenger ribonucleic acid; P, postnatal day; *ARG1*, arginase 1; Arg1, arginase 1; LNP, lipid nanoparticle)